We are live on
!
Find out more
CIA
Capital Impact Advisors Portfolio holdings
AUM
$247M
1-Year Est. Return
31.15%
This Fund
S&P 500
This Quarter
Est. Return
+10.7%
1 Year Est. Return
+31.15%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$286M
AUM Growth
-$122M
(-30%)
Cap. Flow
-$144M
Cap. Flow
% of AUM
-50.52%
Top 10 Holdings %
Top 10 Hldgs %
24.12%
Holding
143
New
41
Increased
10
Reduced
49
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omnicom Group
OMC
|
+$8.21M |
| 2 |
Service Corp International
SCI
|
+$7.9M |
| 3 |
CLLS
Cellectis
CLLS
|
+$6.83M |
| 4 |
SF
Stifel
SF
|
+$6.38M |
| 5 |
Advance Auto Parts
AAP
|
+$6.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intellia Therapeutics
NTLA
|
+$14.5M |
| 2 |
Twist Bioscience
TWST
|
+$10.6M |
| 3 |
NVTA
Invitae Corporation
NVTA
|
+$9.84M |
| 4 |
Veracyte
VCYT
|
+$8.46M |
| 5 |
EXAS
Exact Sciences
EXAS
|
+$8.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.23% |
| 2 | Technology | 20.11% |
| 3 | Consumer Discretionary | 16.12% |
| 4 | Financials | 12.25% |
| 5 | Communication Services | 9.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Pacific Biosciences
PACB
$435M
| – | – |
-300,000
| Closed | -$7.78M |
|
127
PagerDuty
PD
$816M
| – | – |
-165,000
| Closed | -$6.88M |
|
128
Personalis
PSNL
$1.35B
| – | – |
-215,380
| Closed | -$7.88M |
|
|
P
129
Everpure Inc
P
$25.7B
| – | – |
-140,000
| Closed | -$3.17M |
|
130
ResMed
RMD
$30.6B
| – | – |
-16,125
| Closed | -$3.43M |
|
131
RingCentral
RNG
$4.66B
| – | – |
-5,000
| Closed | -$1.9M |
|
132
Schrodinger
SDGR
$1.13B
| – | – |
-25,000
| Closed | -$1.98M |
|
133
Trade Desk
TTD
$8.48B
| – | – |
-73,000
| Closed | -$5.85M |
|
134
Ubiquiti
UI
$33.7B
| – | – |
-8,000
| Closed | -$2.23M |
|
135
VeriSign
VRSN
$26.2B
| – | – |
-16,212
| Closed | -$3.51M |
|
136
XPeng
XPEV
$12.4B
| – | – |
-20,000
| Closed | -$857K |
|
137
Zoom
ZM
$28.2B
| – | – |
-3,000
| Closed | -$1.01M |
|
|
ACCD
138
DELISTED
Accolade Inc
ACCD
| – | – |
-25,500
| Closed | -$1.11M |
|
|
SYRS
139
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-16,860
| Closed | -$1.83M |
|
|
VAPO
140
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| – | – |
-8,750
| Closed | -$1.88M |
|
|
SGEN
141
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-27,679
| Closed | -$4.85M |
|
|
CELL
142
DELISTED
PhenomeX Inc. Common Stock
CELL
| – | – |
-9,100
| Closed | -$814K |
|
|
AVLR
143
DELISTED
Avalara, Inc.
AVLR
| – | – |
-17,026
| Closed | -$2.81M |
|
Similar funds
AI
AB
PWS
BFM
IFPG
SCM
GWS
MC
Capital Impact Advisors's Q1 2021 Portfolio in Review
As of Q1 2021, Capital Impact Advisors held 143 positions worth $286M, down 30% from $407M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Capital Impact Advisors withdrew a net $144M in Q1 2021, closing 34 positions and reducing 49 holdings. Its most notable exit was Personalis, an estimated $7.88M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 45% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Capital Impact Advisors opened a new position in Omnicom Group worth $8.82M.
- Capital Impact Advisors's largest Q1 2021 buy was Omnicom Group: 118,943 shares worth $8.82M.
- Capital Impact Advisors added most to Cellectis in Q1 2021, an estimated $6.83M increase.
- Capital Impact Advisors's biggest Q1 2021 reduction was Intellia Therapeutics, cutting an estimated $14.5M.
- Capital Impact Advisors fully exited Personalis in Q1 2021, selling an estimated $7.88M.
- Capital Impact Advisors's ten largest holdings make up 24% of its $286M portfolio in Q1 2021.
- Capital Impact Advisors opened 41 new positions and closed 34 in Q1 2021.
- Capital Impact Advisors's portfolio value fell 30% quarter-over-quarter to $286M.
Based on Capital Impact Advisors's 13F filing for Q1 2021, filed 18 May 2021.